Yahoo
XETRA - Delayed Quote EUR

SCHOTT Pharma AG & Co. KGaA (1SXP.DE)

21.75 -0.10 (-0.46%)
At close: November 6 at 5:35:06 PM GMT+1
Chart Range Bar
Loading chart for 1SXP.DE
  • Previous Close 21.85
  • Open 21.95
  • Bid 21.75 x --
  • Ask 21.80 x --
  • Day's Range 21.50 - 21.95
  • 52 Week Range 12.62 - 26.20
  • Volume 109,973
  • Avg. Volume 76,661
  • Market Cap (intraday) 3.276B
  • Beta (5Y Monthly) 0.86
  • PE Ratio (TTM) 24.17
  • EPS (TTM) 0.90
  • Earnings Date Dec 10, 2026
  • Forward Dividend & Yield 0.18 (0.83%)
  • Ex-Dividend Date Feb 4, 2026
  • 1y Target Est 25.08

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

www.schott-pharma.com

5,002

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

1SXP.DE
45.86%
DAX P (^GDAXI)
5.43%

1-Year Return

1SXP.DE
20.88%
DAX P (^GDAXI)
8.79%

3-Year Return

1SXP.DE
20.77%
DAX P (^GDAXI)
70.59%

5-Year Return

1SXP.DE
27.50%
DAX P (^GDAXI)
60.83%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 247.88M
Earnings 31.01M
Profit Margin 12.51%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
150M
200M
250M
13.0%
14.0%
15.0%
16.0%
17.0%

Analyst Insights

View More

Analyst Price Targets

17.30 Low
25.08 Average
21.75 Current
29.20 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.40%

  • Return on Assets (ttm)

    6.49%

  • Return on Equity (ttm)

    14.68%

  • Revenue (ttm)

    1.02B

  • Net Income Avi to Common (ttm)

    136.22M

  • Diluted EPS (ttm)

    0.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    24.88M

  • Total Debt/Equity (mrq)

    30.88%

  • Levered Free Cash Flow (ttm)

    -19.74M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: